Meda AB, a listed Swedish drug company, has agreed to acquire Somerset, N.J.-based specialty drug company MedPointe Inc. The deal includes $520 million in cash and 17.5 million Meda shares. The stock is currently valued at around $300 million, and represents around 6% of Meda. MedPointe shareholders include The Carlyle Group, Cypress Group, Frazier Healthcare Ventures, Ferrer Freeman & Co. and company management. www.meda.sewww.medpointepharma.com
Nearly there!
We have just sent you an email so you can verify your account. Please check your spam or junk folder just in case
it’s been delivered there.
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: subscriptions@peimedia.com.
Copyright PEI Media
Not for publication, email or dissemination
Share with other subscribers
Only logged in subscribers of this site will be able to access the shared article.
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: subscriptions@peimedia.com.